AU2003268155A1 - Methods of inhibiting tgf beta with substituted pyrazoles - Google Patents

Methods of inhibiting tgf beta with substituted pyrazoles

Info

Publication number: AU2003268155A1
Authority: AU; Australia
Prior art keywords: methods; tgf beta; substituted pyrazoles; inhibiting tgf; inhibiting
Prior art date: 2002-09-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2003268155A

Inventor

Jason Scott Sawyer

Beverly Ann Teicher

Jonathan Michael Yingling

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eli Lilly and Co

Original Assignee

Eli Lilly and Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-19

Filing date

2003-09-16

Publication date

2004-04-08

2003-09-16 Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co

2004-04-08 Publication of AU2003268155A1 publication Critical patent/AU2003268155A1/en

Status Abandoned legal-status Critical Current

Links

230000002401 inhibitory effect Effects 0.000 title 1
150000003217 pyrazoles Chemical class 0.000 title 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Plural Heterocyclic Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AU2003268155A 2002-09-19 2003-09-16 Methods of inhibiting tgf beta with substituted pyrazoles Abandoned AU2003268155A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US41209802P	2002-09-19	2002-09-19
US60/412,098		2002-09-19
PCT/US2003/026296 WO2004026302A1 (en)	2002-09-19	2003-09-16	Methods of inhibiting tgf beta with substituted pyrazoles

Publications (1)

Publication Number	Publication Date
AU2003268155A1 true AU2003268155A1 (en)	2004-04-08

Family

ID=32030805

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2003268155A Abandoned AU2003268155A1 (en)	2002-09-19	2003-09-16	Methods of inhibiting tgf beta with substituted pyrazoles

Country Status (2)

Country	Link
AU (1)	AU2003268155A1 (en)
WO (1)	WO2004026302A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CL2004000234A1 (en) *	2003-02-12	2005-04-15	Biogen Idec Inc	DERIVATIVE COMPOUNDS 3- (PIRIDIN-2-IL) -4-HETEROARIL-PIRAZOL SUBSTITUTED, ANTAGONISTS OF AIK5 AND / OR AIK4; PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND IN THE TREATMENT OF FIBROTIC DISORDERS AS SCLERODERMIA, LUPUS NEFRITICO, CICATRIZACION DE HERID
TW200639163A (en)	2005-02-04	2006-11-16	Genentech Inc	RAF inhibitor compounds and methods
EP3254696A1 (en)	2006-10-03	2017-12-13	Genzyme Corporation	Use of tgf beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia
US20140308275A1 (en)	2011-07-27	2014-10-16	Inserm (Institut National De La Sante Et De La Recherche Medicale	Methods for diagnosing and treating myhre syndrome
CA2853484C (en)	2011-10-26	2018-08-21	Seattle Children's Research Institute	Cysteamine in the treatment of fibrotic disease
WO2016160881A1 (en)	2015-04-01	2016-10-06	Rigel Pharmaceuticals, Inc.	TGF-β INHIBITORS
EP3313420B1 (en)	2015-06-25	2024-03-13	The Children's Medical Center Corporation	Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
WO2017151409A1 (en)	2016-02-29	2017-09-08	University Of Florida Research Foundation, Incorporated	Chemotherapeutic methods
EP4049665B1 (en)	2016-03-15	2025-03-12	The Children's Medical Center Corporation	Methods and compositions relating to hematopoietic stem cell expansion
KR20210076069A (en) *	2018-10-18	2021-06-23	난징 산홈 팔마세우티칼 컴퍼니 리미티드	Compounds as TGF-βR1 inhibitors and their application
US20220177978A1 (en)	2019-04-02	2022-06-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of predicting and preventing cancer in patients having premalignant lesions
CA3160963A1 (en)	2019-11-28	2021-06-03	Origo Biopharma, S.L.	Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
JP2023541463A (en) *	2020-09-17	2023-10-02	ヤンセンファーマシューティカエヌ．ベー．	casein kinase 1 delta modulator
EP3978487A1 (en)	2020-09-30	2022-04-06	Origo Biopharma, S.L.	2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
WO2025111251A1 (en) *	2023-11-20	2025-05-30	Exelixis, Inc.	Compounds that inhibit polo-like kinase 4

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2291115A1 (en) *	1997-05-22	1998-11-26	G.D. Searle & Co.	Substituted pyrazoles as p38 kinase inhibitors

2003
- 2003-09-16 AU AU2003268155A patent/AU2003268155A1/en not_active Abandoned
- 2003-09-16 WO PCT/US2003/026296 patent/WO2004026302A1/en not_active Ceased

Also Published As

Publication number	Publication date
WO2004026302A1 (en)	2004-04-01

Publication	Publication Date	Title
AU2003292429A1 (en)	2004-07-14	Pyrazole compounds
PL377778A1 (en)	2006-02-20	Pyrazole derivatives
AU2003284976A1 (en)	2004-05-13	Expandable sheath tubing
AU2003296586A1 (en)	2004-06-15	Pyridazinone derivatives as cdk2-inhibitors
PL375979A1 (en)	2005-12-12	Pyrazole derivatives as transforming growth factor (tgf) inhibitors
AU2003268155A1 (en)	2004-04-08	Methods of inhibiting tgf beta with substituted pyrazoles
AU2003283626A1 (en)	2004-06-23	Catheter
AU2003301968A1 (en)	2004-06-03	4-aminomethyl-1-aryl-cyclohexylamine derivatives
AU2003243000A1 (en)	2003-12-31	Tape feeder
AU2003240668A1 (en)	2003-12-02	Attenuation of metapneumovirus
AU2003273885A1 (en)	2004-04-23	Morpholine-bridged indazole derivatives
AU2003248537A1 (en)	2003-12-31	Bushing
AU2002353510A1 (en)	2003-12-12	Nebuliser
AU2003234131A1 (en)	2003-11-03	5-o-mycaminosyltylonide derivatives
AU2003267722A1 (en)	2004-04-23	Imidazol-1-ylmethyl pyridazine derivatives
AU2003220483A1 (en)	2003-11-11	Substituted pyrazolyl compounds for the treatment of inflammation
AU2003244140A1 (en)	2004-01-06	Catheter
AU2002953066A0 (en)	2002-12-19	Reel
AU2002953019A0 (en)	2002-12-12	Azole derivatives
AU2002951868A0 (en)	2002-10-24	Compound i
AU2003284704A1 (en)	2004-06-23	Substituted 1h-pyridine-2-one derivatives
AU2003288012A1 (en)	2004-06-15	Isothiazolyl-benzoxazine derivatives
AU2003280323A1 (en)	2004-06-15	Dispersion compensating biosensor
AU2001281123A1 (en)	2002-02-18	Haplotypes of the isl1 gene
AU2003206908A1 (en)	2003-09-16	Insoluble-solid-free electrodip coatings

Legal Events

Date	Code	Title	Description
2005-06-16	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase